# Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines

> **NCT01502345** · PHASE1 · COMPLETED · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 31 (actual)

## Conditions studied

- Hemorrhagic Fever With Renal Syndrome

## Interventions

- **BIOLOGICAL:** Vaccine/device combination for prevention of HFRS

## Key facts

- **NCT ID:** NCT01502345
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2013-01-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01502345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01502345, "Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01502345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*